See more : VGP NV (0HM0.L) Income Statement Analysis – Financial Results
Complete financial analysis of Aadi Bioscience, Inc. (AADI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aadi Bioscience, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- CNH Industrial N.V. (CNHI) Income Statement Analysis – Financial Results
- Alligator Energy Limited (AGE.AX) Income Statement Analysis – Financial Results
- Seera Holding Group (1810.SR) Income Statement Analysis – Financial Results
- Epigral Limited (EPIGRAL.BO) Income Statement Analysis – Financial Results
- GMM Grammy Public Company Limited (GRAMMY.BK) Income Statement Analysis – Financial Results
Aadi Bioscience, Inc. (AADI)
About Aadi Bioscience, Inc.
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24.35M | 15.22M | 1.00M | 14.00M | 749.00K | 20.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.81M | 1.34M | 276.00K | 176.00K | 76.50K | 0.00 | 51.27K | 69.67K | 57.98K | 23.97K | 22.82K | 22.39K | 23.59K | 20.51K | 0.00 | 0.00 |
| Gross Profit | 21.55M | 13.88M | 724.00K | 13.82M | 672.50K | 20.16M | -51.27K | -69.67K | -57.98K | -23.97K | -22.82K | -22.39K | -23.59K | -20.51K | 0.00 | 0.00 |
| Gross Profit Ratio | 88.47% | 91.23% | 72.40% | 98.74% | 89.79% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 48.93M | 32.66M | 19.67M | 15.01M | 12.82M | 17.85M | 12.15M | 11.37M | 11.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 18.51M | 2.12M | 1.85M | 13.49M | 9.24M | 29.49K | 23.01K | 22.82K | 22.39K | 23.59K | 20.51K | 20.51K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 7.83M | -46.69K | -51.27K | 5.17M | 5.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 44.55M | 40.18M | 18.51M | 2.12M | 9.68M | 13.44M | 9.19M | 5.20M | 5.80M | 22.82K | 22.39K | 23.59K | 20.51K | 20.51K | 0.00 | 0.00 |
| Other Expenses | 0.00 | 5.06M | -120.00K | -580.00K | -142.73K | -6.39K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -33.62K |
| Operating Expenses | 93.48M | 72.84M | 38.06M | 16.55M | 22.50M | 31.29M | 21.34M | 16.56M | 17.43M | 22.82K | 22.39K | 23.59K | 20.51K | 20.51K | 0.00 | -33.62K |
| Cost & Expenses | 96.29M | 74.17M | 38.06M | 16.55M | 22.58M | 31.34M | 21.39M | 16.63M | 17.49M | 22.82K | 22.39K | 23.59K | 20.51K | 41.02K | 0.00 | -33.62K |
| Interest Income | 6.40M | 2.40M | 13.00K | 41.00K | 1.03M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 231.00K | 230.00K | 665.00K | 815.00K | 0.00 | 778.22K | -105.78K | 9.94K | 8.43K | 5.88K | 4.97K | 3.60K | 1.89K | 1.89K | 0.00 | 0.00 |
| Depreciation & Amortization | 169.00K | 159.00K | 276.00K | 176.00K | 76.50K | 46.69K | 51.27K | 69.67K | 57.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -65.37M | -60.12M | -109.15M | -2.49M | -24.44M | -10.35M | -21.24M | -16.43M | -17.01M | -22.82K | -22.39K | -23.59K | -20.51K | -41.02K | 0.00 | -33.62K |
| EBITDA Ratio | -268.40% | -371.71% | -3,546.30% | -18.94% | -3,004.55% | -55.24% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -71.93M | -58.96M | -111.22M | -2.55M | -22.58M | -11.18M | -21.39M | -16.63M | -17.49M | -22.82K | -22.39K | -23.59K | -20.51K | -41.02K | 0.00 | -33.62K |
| Operating Income Ratio | -295.36% | -387.47% | -11,121.70% | -18.21% | -3,014.77% | -55.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.17M | 2.17M | 1.13M | -927.00K | 1.17M | 784.61K | -12.07K | -349.93K | 416.33K | 17.15K | 16.95K | 17.42K | 19.99K | 18.62K | 0.00 | 0.00 |
| Income Before Tax | -65.77M | -60.51M | -110.09M | -3.48M | -23.27M | -10.40M | -21.40M | -16.98M | -17.07M | -28.70K | -27.37K | -27.19K | -22.40K | -22.40K | 0.00 | -33.62K |
| Income Before Tax Ratio | -270.04% | -397.69% | -11,008.80% | -24.83% | -3,106.88% | -51.58% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -3.50M | 2.00K | 2.00K | 1.30K | 778.22K | -12.06K | -3.00 | 3.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -65.77M | -57.01M | -110.09M | -3.48M | -23.27M | -10.40M | -21.40M | -16.98M | -17.07M | -28.70K | -27.37K | -27.19K | -22.40K | -22.40K | 0.00 | -33.62K |
| Net Income Ratio | -270.04% | -374.67% | -11,009.00% | -24.84% | -3,106.88% | -51.58% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.44 | -2.53 | -12.34 | -20.52 | -8.60 | -4.60 | -14.81 | -9.42 | -9.47 | -0.02 | -0.02 | -0.02 | -0.01 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -2.44 | -2.53 | -12.34 | -20.52 | -8.60 | -4.60 | -14.81 | -9.42 | -9.47 | -0.02 | -0.02 | -0.02 | -0.01 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 26.92M | 22.51M | 8.92M | 169.49K | 2.71M | 2.26M | 1.44M | 1.80M | 1.80M | 1.80M | 1.80M | 1.80M | 1.80M | 5.00M | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 26.92M | 22.51M | 8.92M | 169.49K | 2.71M | 2.26M | 1.44M | 1.80M | 1.80M | 1.80M | 1.80M | 1.80M | 1.80M | 5.00M | 0.00 | 0.00 |
Aadi Bioscience, Inc. (AADI) Q3 2023 Earnings Call Transcript
Aadi Bioscience, Inc. (NASDAQ:AADI ) Q3 2023 Earnings Conference Call November 8, 2023 8:30 AM ET Company Participants Marcy Graham - Senior Vice President, Investor Relations and Corporate Communications Scott Giacobello - CFO Dave Lennon - President and CEO Loretta...
Aadi Bioscience Reports Financial Results for the Third Quarter 2023 and Provides Corporate Update
PRECISION1 trial of nab-sirolimus in solid tumors with TSC1 or TSC2 inactivating alterations on track for presentation of early interim analysis by mid-December 2023; multiple 2024 catalysts expected Latest real-world, next generation sequencing (NGS) analysis reinforces large unmet need in TSC1...
Aadi Bioscience to Participate in Jefferies London Healthcare Conference
LOS ANGELES , Nov. 6, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, announced today participation in the Jefferies London Healthcare...
Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting
Aadi initiates Phase 2 trial investigating the combination of nab-sirolimus with letrozole for the treatment of advanced or recurrent endometrioid-type endometrial cancer (EEC) LOS ANGELES , Oct. 19, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing...
Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Two new real-world next-generation sequencing studies reinforce prevalence of TSC1/2 mutations in up to 2% of all tumors, a significant addressable cancer population PRECISION1 tumor-agnostic trial testing nab-sirolimus for patients with TSC 1/2 mutations on track for interim analysis on...
Aadi Bioscience Announces Poster Presentations at the North American Neuroendocrine Tumor Society (NANETS) 2023 Multidisciplinary NET Medical Symposium
LOS ANGELES , Oct. 5, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced that two posters will be presented at the upcoming North...
Aadi Bioscience Grants New CEO Dave Lennon, Ph.D. Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)
LOS ANGELES , Oct. 3, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced that an equity award has been granted to its...
Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer
Dr. Lennon brings over 20 years of pharmaceutical experience, including deep expertise in the development and commercialization of mTOR inhibitors Leadership transition expected to accelerate growth and leverage ground-breaking nanoparticle technology in FYARRO® to build a leading precision oncology company...
Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
LOS ANGELES , Sept. 20, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced that four abstracts have been selected for presentation at...
Aadi Bioscience to Participate at Upcoming Investor Conferences
LOS ANGELES , Sept. 5, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with mTOR pathway alterations, announced today participation at the following investor events: H.C.
Source: https://incomestatements.info
Category: Stock Reports